Pathological Gambling In A Patient With Parkinson’s Disease And Valproate Response

Yildiz Degirmenci, Hulusi Kececi

To appear in: Dusunen Adam The Journal of Psychiatry and Neurological Sciences

DOI: 10.14744/DAJPNS.2019.00053

Cite this article as: Degirmenci Y, Kececi H. Pathological Gambling In A Patient With Parkinson’s Disease And Valproate Response, Dusunen Adam The Journal of Psychiatry and Neurological Sciences, DOI: 10.14744/DAJPNS.2019.00053

This is a PDF file of an unedited manuscript that has been accepted by the Dusunen Adam The Journal of Psychiatry and Neurological Sciences editor for publication. As a service to our researchers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable version. Please note that during the production process, typos or errors may be discovered which could affect the content, and all legal disclaimers pertaining to the manuscript.
Pathological Gambling In A Patient With Parkinson’s Disease And Valproate Response

Yıldız Değirmenci¹, Hulusi Keçeci²

¹ Assoc. Prof., MD, Düzce University Faculty of Medicine, Neurology Department, Düzce, Turkey.
² Prof., MD, Düzce University Faculty of Medicine, Neurology Department, Düzce, Turkey.

Corresponding Author: Yıldız Değirmenci, Assoc.Prof., MD
Düzce University Faculty of Medicine
Neurology Department
Düzce, Turkey.
Tel: 0 380 542 13 90
Fax: 0 380 542 13 85
E-mail: vdegi@gmail.com

The manuscript was presented as poster in the 52th National Neurology Congress, November 25-December 1, 2016, Antalya, Turkey.

PATHOLOGICAL GAMBLING IN A PATIENT WITH PARKINSON’ S DISEASE AND VALPROATE RESPONSE

ABSTRACT

Sodium valproate is a well-known antiepileptic agent with multiple mechanism of action such as sodium channel blockage, gamma-aminobutyric acid activity induction. Despite its’ well-described anxiolytic and mood stabilization effects, its’ mechanism of action on pathological gambling is not clear. However, it has been reported as an effective treatment option on pathological gambling in patients without Parkinson’s disease (PD). We presented a young man with the diagnosis of PD suffering from pathological gambling as an impulse
control disorder due to anti-pakinsonian drugs, who did not respond to drug adjustments, but showed a complete improvement with sodium valproate, without any worsening in PD symptoms.

Key-words: Parkinson’s disease, impulse control disorders, pathological gambling, sodium valproate.

BIR PARKINSON HASTASINDA PATOLOJIK KUMAR OYNAMA VE SODYUM VALPROAT CEVABI

ÖZET

Sodyum valproat, sodyum kanal blokaji, gama-aminobütirik asit aktivitesi indüksiyonu gibi çoklu etki mekanizması olan iyi bilinen bir antiepileptic ajandır. İyi tanımlanmış anksiyolitik ve duygudurum düzenleyici etkisine rağmen, patolojik kumar oynama üzerindeki etki mekanizması açık değildir. Bununla birlikte, Parkinson hastalığı (PH) olmayan hastalardaki patolojik kumar oynamada etkin bir tedavi seçeneği olarak bildirilmiştir. Biz PH tanısı almış, anti-parkinson ilaçlara bağlı dürtü kontrol bozukluğu olarak patolojik kumar oynamadan yakınan, ilaç ayarlamalarına cevap vermeyen fakat sodium valproat ile; PH semptomlarında herhangi bir kötüleşme olmadan tam düzelme gösteren genç bir erkek hastayı sunduk.

Anahtar Kelimeler: Parkinson hastalığı, dürtü kontrol bozukluğu, patolojik kumar oynaması, sodium valproate.

INTRODUCTION

Idiopathic Parkinson’s disease (IPD) is a chronic, neurodegenerative, progressive disorder due to the dysfunction of dopaminergic transmission in basal ganglia, and characterized with cardinal motor symptoms including bradykinesia, rest tremor, rigidity, and postural instability, as well as the non-motor symptoms such as hyposmia, mood disorders, cognitive, autonomic dysfunction, sleep problems, and many others. As the disease progresses, patients are prone to expose dopaminergic therapy induced complications including motor fluctuations, levodopa-induced dyskinesia, and impulse control disorders (ICDs) (1).

Impulse control disorders are a number of repetitive and reward-based behaviours, which are reported to occur in a prevalence of 8.1 % and 35 % among patients with PD (2). Hypersexuality, compulsive shopping, binge eating and pathological gambling are known as the major ICDs, however hobbyism, punding, hoarding, and dopamine dysregulation syndrome are also classified in the broad spectrum of ICDs, which are common in patients with PD, in the course of the disease (3). The pathophysiology of ICDs is thought to be associated with the use of antiparkinsonian dopaminergic drugs, affecting the mesocorticolimbic dopamine system, in particular, although the role possible genetic predisposition and neural alterations due to the disease that may lead to neurobiological sensitivity are not clear (4).

Although the primary treatment of ICDs is the cessation of the offending antiparkinsonian drugs, dopamine agonists in particular, and levodopa to a lesser extent, some patients can’t tolerate this discontinuation due to the worsening of motor syndrome or withdrawal syndrome. Since some patients may be unresponsive to dopaminergic treatment modification, other drugs including antidepressants, and antiepileptic agents may be helpful in addition to dopaminergic drug modification (5).
Since there is limited number of reports revealing topiramate, fluvoxamine in the treatment of ICDs in IPD patients and sodium valproate in patients without PD (5, 6), we here reported a young PD patient suffering from pathological gambling which was unresponsive to dopaminergic treatment modification, but showed a complete recovery with sodium valproate treatment.

CASE REPORT

A 52-year old, right handed man presented to our movement disorders outpatient clinic with the complaint of inappropriate behaviours such as compulsive shopping, selling household goods, and pathological gambling which gradually worsened within last 6 months. He was suffering from terrifying visual hallucinations that were marked at nights but also exist in the day time. He had the diagnosis of IPD based on the clinical findings of asymmetrical Parkinsonism with resting tremor of the limbs, and gradually worsened slowing which began 3 years ago, and he was under dopaminergic treatment since then. His medical records revealed that he was taking combined levodopa (Levodopa+carbidopa+enthacapone, © Stalevo) 100 mg three times a day, 1 mg rasagiline once daily, and 2 different types of dopaminergic agonists ( 50 mg pribedile three times a day, and 1mg pramipexole three times a day) simultaneously since last 1 year. His medical and family history was unremarkable otherwise. He had no medical comorbidities. His neurological examination revealed a marked resting tremor in his left hand, bilateral rigidity and bradykinesia, pronounced in the left side, anteflexion posture deteriorating gate. Psychiatric assessment of the patient was consistent with anxiety, psychosis, and impulsive behaviours including the irresistible urge to spend all the money he has, and pathological gambling. The pathological gambling habit of the patient existed since 6 months, with day to night gambling in internet, horse race bets, and cards. He began to lose increasing amounts of money leading to a marked deterioration in the family’s income, as well as the relationships of the family members. Since these impulsive behaviours were attributed to the inappropriate and excessive amount of dopaminergic treatment, pribedil e and rasagiline were discontinued and in the follow-ups, pramipexole dose was gradually lowered to 1 mg once a day, and discontinued within 4 weeks. As a consequence of dopaminergic drug management, compulsive shopping, selling household goods, and spending excessive money symptoms were found to be improved but pathological gambling was resistant. Additionally, his Parkinsonism symptoms were gradually worsened. Therefore, the combined LD doses were titrated up to 125 mg three times a day, and 25 mg quetiapine at night time was introduced for hallucinations and psychosis. These changes in treatment regimen led to an improvement in the motor symptoms of Parkinsonism and the psychosis. However, he was still gambling in internet, and betting on horse races, and loosing increasing amounts of money. Thus extended-release sodium valproate (©Depakin Chrono BT) was introduced 500 mg per day for the resistant pathological gambling behaviour. In the second-week of follow up visit, the patient and his wife reported that the urge of the patient for gambling began to decrease, and completely dissolved within 1 month.

DISCUSSION

Pathological gambling is an important ICD with a prevalence of 3.4-6.1 % among patients with PD, and defined as an excessive, uncontrolled gambling despite financial losses and social problems in International classification of diseases-10 (7, 8).
Pathophysiology of pathological gambling is still a myth with the potential involvement of serotonergic, dopaminergic and opioid dysfunction. However, there is a growing interest to the neural pathways underlying motivation, reward, decision-making and impulsivity. Among these, dysregulation of the mesocorticolimbic dopamine system is thought to be the major neurobiological factor as for other ICDs in PD (9, 10).

Despite the lack of definite and clarified aetiology of pathological gambling in patients with PD, the most causative agents reported are dopaminergic agents, dopaminergic agonists in particular (11). However, short-acting levodopa, monoamine oxidase-B inhibitors, amantadine have also shown to be responsible (10). As a gold standard approach, the first-line treatment of ICDs in PD is the discontinuation of the inducing drugs in which careful monitorization is mandatory to avoid withdrawal syndrome or the worsening of PD symptoms. In addition to behavioural therapy, pharmacological agents shown to be effective in the treatment of ICDs including pathological gambling are selective serotonin reuptake inhibitors as fluvoxamine, citalopram and mood stabilizers as carbamazepine, lithium that are thought to be effective due to their effects on noradrenergic system or limbic antikindling effects (12-15).

Sodium valproate is a well-known antiepileptic drug with multiple mechanism of action including sodium channel blockage, increasing the release of inhibitory neurotransmitter GABA, and block T-type Ca2+ channels (16). Beyond its’ antiepileptic effects, sodium valproate is an effective mood stabilizer that is also shown to improve pathological gambling in patients without PD (14, 16).

According to our knowledge and literature review, there is no report of sodium valproate as a therapeutic option on pathological gambling in patients with PD. Besides, it has been known as a drug that in encountered in the list of drugs inducing parkinsonism (12). However, we here reported a young patient with PD experiencing pathological gambling that was unresponsive to the drug adjustments but responded well to sodium valproate with complete recovery, and without any worsening of PD symptoms. Since this is an only case-report, further studies in the future with larger number of PD patients should be helpful to clarify the effects of sodium valproate on pathological gambling in PD.

**Informed Consent:** Written consent was obtained from the patient.

**Peer-review:** Externally peer-reviewed.

**Conflict of Interest:** Authors declared no conflict of interest.

**Financial Disclosure:** Authors declared no financial support.

**REFERENCES**

1. Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan, Lang AE, Halliday G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR, Adler CH, Deuschl G. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord 2015; 30:1591-1601.
2. Maloney EM, Djamshidian A, O'Sullivan SS. Phenomenology and epidemiology of impulsive
non-Parkinsonian populations. J Neurol Sci 2017; 374:47–52.

3. Voon V, Fox SH. Medication-related impulse control and repetitive behaviors in Parkinson
disease. Arch Neurol 2017; 64:1089–1096.

4. Vriend C. The neurobiology of impulse control disorders in Parkinson's disease: from neurotransmitters to neural networks. Cell Tissue Res 2018; 373:327-336.

5. Ramirez-Zamora A, Gee L, Boyd J, Biller J. Treatment of impulse control disorders in Parkinson's disease: Practical considerations and future directions. Expert Rev Neurother 2016; 16:389-399.

6. Pallanti S, Quercioli L, Sood E, Hollander E. Lithium and valproate treatment of pathological gambling: a randomized single-blind study. J Clin Psychiatry 2002; 63:559-564.

7. World Health Organization. International Classification of Diseases (ICD-10). Clinical
descriptions and diagnostic guidelines. Geneva: World Health Organization, 1992.

8. Avanzi M, Baratti M, Cabrini S, Uber E, Brighetti G, Bonfà F. Prevalence of pathological gambling in patients with Parkinson’s disease. Mov Disord 2006; 21:2068-2072.

9. Zurowski M, O'Brien JD. Developments in impulse control behaviours of Parkinson's disease. Curr Opin Neurol 2015; 28:387-392.

10. Weintraub D, Claassen DO. Impulse control and related disorders in parkinson's disease. Int Rev Neurobiol. 2017; 133:679-717.

11. Iancu I, Lowengrub K, Dembinsky Y, Kotler M, Dannon PN. Pathological gambling: an update on neuropathophysiology and pharmacotherapy. CNS Drugs 2008; 22:123-138.

12. Montastruc JL, Sommet A, Olivier P, Bagheri H, Gony M, Lapeyre-Mestre M, Brefel-Courbon C, Ferreira J, Schmitt L, Senard JM, Rascol O. Drugs, Parkinson's disease and parkinsonian syndroms: recent advances in pharmacovigilance. Therapie 2006; 61:29-38. (French)
13. Goodman WK, Ward H, Kablinger A, Murphy T. Fluvoxamine in the treatment of obsessive-compulsive disorder and related conditions. J Clin Psychiatry 1997; 58(Suppl.5):32-49.

14. Pallanti S, Quercioli L, Sood E, Hollander E. Lithium and valproate treatment of pathological gambling: a randomized single-blind study. J Clin Psychiatry 2002; 63:559-564.

15. V. Zimmerman M, Breen RB, Posternak MA. An open-label study of citalopram in the treatment of pathological gambling. J Clin Psychiatry 2002; 63:44-48.

16. Deshmukh R, Thakur AS, Dewangan D. Mechanism of action of anticonvulsant drugs: a review. Int J Pharm Sci Res 2011; 2:225-236.